Assuntos
Antibacterianos/uso terapêutico , Transplante de Fígado , Oxazolidinonas/uso terapêutico , Tetrazóis/uso terapêutico , Tuberculose Pulmonar/tratamento farmacológico , Adolescente , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Duração da Terapia , Humanos , Hospedeiro Imunocomprometido , Transplante de Fígado/efeitos adversos , Oxazolidinonas/administração & dosagem , Oxazolidinonas/efeitos adversos , Tetrazóis/administração & dosagem , Tetrazóis/efeitos adversos , Resultado do Tratamento , Tuberculose Pulmonar/complicaçõesRESUMO
BACKGROUND AND OBJECTIVE: We compared the efficacy and safety of standard vs. extended primary cytomegalovirus (CMV) prophylaxis in solid organ transplantation. MATERIALS AND METHODS: Retrospective cohort study of CMV seronegative recipients who received CMV prophylaxis after solid organ transplantation from seropositive donor (D+/R-) (2007-2017). CMV infection in the first two years after transplantation in recipients with prophylaxis longer or shorter than 100 days were compared. RESULTS: CMV infection occurred in 29 of 66 patients (43.9%) with prophylaxis. Forty-five patients (68.2%) received extended prophylaxis. CMV infection and disease rates were not different between patients with extended and standard prophylaxis. However, extended prophylaxis was associated with a higher rate of myelotoxicity (68.9% vs. 42.9%, p<0.05). CONCLUSIONS: Extending primary CMV prophylaxis over 100 days did not prevent late-onset infection but it was associated with hematological toxicity.